PLETHICO

Plethico Pharmaceuticals Limited has informed the Exchange that With a view to address the delay in repayment of principal and interest on fixed deposits, service banking facilities, pay statutory dues and sustain its business operations, the Company has opted to adopt contract manufacturing model for its operation.

Plethico Pharmaceuticals Limited has informed the Exchange regarding the details of authorized Key Managerial Personnel for the purpose of determining materiality of an event or information and for the purpose of making disclosures to the Stock Exchanges.

Plethico Pharmaceuticals Limited has informed the Exchange regarding Corporate Updates- 1. Acquisition of M/s Natrol Inc, USA by M/s. Aurobindo Pharma. 2.Merging of Administrative Office of the Company with the Registered Office Of the Company.

Plethico Pharmaceuticals Limited has informed the Exchange regarding Postponement of Board Meeting Scheduled to be held on May 29, 2015 for the purpose of approval of Audited Financial Results of the Company for the Quarter and Year ended on March 31, 2015.

Plethico Pharmaceuticals Limited has informed the Exchange that the Ministry of Corporate Affairs, New Delhi ("MCA") has taken the "Green Initiative in the Corporate Governance" vide Circular No. 17/2011 dated April 21, 2011 and Circular No.18/2011 dated April 29, 2011 allowing paperless compliances by companies through electronic mode. Companies are now permitted to send all communications/documents including the Notice calling the General Meeting (including AGM), audited financial statements, directors' report, auditors' report etc. through electronic mode to their shareholders. Further, the

Plethico Pharmaceuticals Limited has informed the Exchange that Mr. Rajiv Bedi, President and Mr. Hemant Modi, Chief Operating Officer of the Company have resigned from the Company w.e.f. April 30, 2011 and May 31, 2011, respectively. Hence they have ceased to be KMPs of the Company under the said designation.

Plethico Pharmaceuticals Limited has submitted to the Exchange vide its letter dated April 13, 2011 a copy of Corporate Presentation of the Company.

Plethico Pharmaceuticals Limited had informed the Exchange regarding press release for the audited financial results of the Company for quarter and accounting year ended on December 31, 2010. The Company has now submitted to the Exchange a copy of Addendum to Press Release for the audited financial results for the quarter and accounting year ended December 31, 2010.

Plethico Pharmaceuticals Limited had submitted to the Exchange a copy of Corporate Presentation containing latest information regarding business overview, growth strategy, Key Financials etc. of the Company. The Company has now submitted to the Exchange a copy of Revised Corporate Presentation, after certain amendments/ updations made in the Presentation.

Plethico Pharmaceuticals Limited has informed the Exchange regarding "Medical Research Institute (MRI) Appoints Fitness Competitor/Trainer Kyle Clarke as an Athlete Spokesperson for the Brand".

Plethico Pharmaceuticals Limited has submitted to the Exchange a copy of Corporate Presentation containing latest information regarding business overview, growth strategy, Key Financials etc. of the Company.

Plethico Pharmaceuticals Limited has informed the Exchange that "Plethico Pharmaceuticals Limited has received the approval for GMP clearance from the Therapeutic Goods Administration (TGA), Department of Health and Ageing, Australian Government for Company's manufacturing unit situated at Indore-Ahmedabad Road, NH 59 Village Dharavara, Post Kalaria, Indore (M.P.)".

Plethico Pharmaceuticals Limited has submitted to the Exchange a copy of the Corporate Presentation Containing latest information regarding business overview, growth strategy, Key Financials etc. of the Company.

Plethico Pharmaceuticals Limited has informed the Exchange vide its letter dated August 26, 2010, that "MRI and Prolab to Feature MMA Fighters, Prize Raffles, and Product Samples at Boston UFC Fan Expo, in Partnership with FIGHT! Magazine".

Plethico Pharmaceuticals Limited has informed the Exchange vide its letter dated June 28, 2010 regarding its Corporate Updates titled "Walmart Stores to Provide Natrol on Shelf with Vitamins in U.S.".

Plethico Pharmaceuticals Limited has informed the Exchange that the Company has received the Certificate of GMP Compliances of a Manufacturer issued by Medicines and Healthcare Products Regulatory Agency(MHRA), U.K. for complying with the principles and guidelines of Good Manufacturing Practice for Capsules- Hard shell, Tablets.

Plethico Pharmaceuticals Limited has submitted to the Exchange a copy of a Corporate Presentation containing latest information regarding business overview, growth strategy, financial analysis etc. of Plethico Pharmaceuticals Limited for the updates of Q4 CY 2009 and YTD December, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/plethico_presentaion_16042010.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange that "Natrol Inc. USA, a premier marketer, manufacturer, and distributor of nationally branded nutritional products, has been recently certified Organic by Oregon Tilth Certified Organic (OTCO) "Class OP-Organic Processor" for its organic products processed i.e. processing and manufacturing of dietary supplements. Natrol Inc., USA is a wholly owned subsidiary of Plethico Pharmaceuticals Limited".

Plethico Pharmaceuticals Limited has informed the Exchange that " Plethico Pharmaceuticals Limited has been included in the 'Pan American Health Organization' (PAHO) procurement office's list of pre-qualified manufacturer. This is a step to cater our products to the said esteemed organization".

Plethico Pharmaceuticals Limited has informed the Exchange that "Plethico Pharmaceuticals Limited has been accorded the status of "Trading House" for a period of 5 years (upto 31st March 2014) in terms of Foreign Trade Policy 2009-2014. The certification to this effect has been issued by The Directorate General of Foreign Trade, Government of India, Ministry of Commerce & Industry."

Plethico Pharmaceuticals Limited has informed the Exchange that: "The manufacturing unit of the Company situated at Kandla Special Economic Zone has been awarded with the "Top Exporter Award" for the year 2007-08 for combined category of manufactured products & services by the Office of Development Commissioner, Kandla Special Economic Zone, Ministry of Commerce and Industry. Plethico Pharmaceuticals Limited has won this award consecutively for the second time. Earlier also Company had won awarded the Top Exporter Award for the year 2003-04."

Plethico Pharmaceuticals Limited has informed the Exchange that Natrol Global FZ LLC, manufacturers of herbal products, shall base their regional headquarters at DuBiotech to cater to the increasing demand for nutritional supplements in the Middle East and Africa regions. Natrol Global is a sister company of Natrol Inc, US, and a subsidiary of Plethico Pharmaceuticals Ltd. a herbal/nutraceutical focus company that engages in the manufacturing, marketing and distribution of pharmaceutical and allied healthcare products. Nutraceuticals are health food supplements that include products such as fu

Plethico Pharmaceuticals Limited has informed the Exchange that: "Plethico Pharmaceuticals Limited has entered into a tie up with Pharma MNC "Molekule (India) Pvt. Ltd., Mumbai" a leading pharmaceutical company having aggressive marketing and distribution network across the country, for marketing some of Natrol's brands in India. The Company is looking to do more tie up's with other Pharma majors in India for promoting it's wellness brands in India".

Plethico Pharmaceuticals Limited has informed the Exchange that "Plethico Pharmaceuticals Limited had entered into a Market Co-operation agreement with Shreya Life Sciences Private Limited on November, 2003 for a period of five years, whereby the entire range of Products of Plethico Pharmaceuticals Limited were retrained from being promoted/ marketed in Domestic Market." "The Non- Compete Agreement with Shreya Life Sciences Private Limited has ceased to be into effect w.e.f November, 2008".

Plethico Pharmaceuticals Limited has informed the Exchange that "The company has appointed Dr. Sharad Kasarle an eminent and distinguished professional having expertise in Neutraceutical and Herbal Products, as a "Consultant - Neutraceuticals" to look after and monitor R&D activities of Neutraceutical and Herbal segments". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). <a href=/content/corporate/Plethico_Updates_15072008.zip target=NEW> For more detail

Plethico Pharmaceuticals Limited has informed the Exchange that Company's Corporate presentation have been compiled containing latest information regarding business overview, growth strategy, financial analysis etc. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/plethico_UP_30062008.zip target=NEW> For more details click here.</a>

Plethico Pharmaceuticals Limited has informed the Exchange that:- "As an ongoing strategic move Plethico Pharmaceuticals Limited is ready to launch Natrol's entire range of herbal and nutraceutical products including "PROLAB", in its market including India, CIS, SEA and GCC. The said launch will done in phased manner".

Plethico Pharmaceuticals Limited has informed the Exchange that : "The manufacturing unit of the Company situated at Kandla Special Economic Zone has been awarded with the "Top Exporter Award" for the year 2006-07 for Chemicals, Drugs, Pharmaceuticals & Allied Sector by the Office of Development Commissioner, Kandla Special Economic Zone, Ministry of Commerce and Industry. The Top Exporter award has been received on behalf of the Company by Shri Hemant Modi, Chief Operating Officer of the Company at the 43rd Foundation Day celebrations on 7th March, 2008."

Plethico Pharmaceuticals Limited has informed the Exchange that the company's medicated lozenges and confectionery has always been a high revenue-earning generator and has been growing at a very fast space for all the markets including India. Due to tremendous growth in demand of the aforesaid segment, the company is facing capacity crunch and in view of this company is evaluating the best proposal location for this state-of-the-art manufacturing facility. The further details on the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements an